ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
bringing together oncologists and oncology-focused healthcare professionals across the Empire State
Meetings & Education
State Society Education Series
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
Financial Advocacy & Patient Assistance
ESHOS Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Atezolizumab Plus Nab-paclitaxel for TNBC
On March 8, the FDA approved atezolizumab (Tecentriq, Genentech Inc.) plus nab-paclitaxel (Abraxane, Celgene) for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
Read OncLive news coverage here